Work

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.3507

Authors: Julien Taieb, Karine Le Malicot, Frederique Madeleine Penault-Llorca, Olivier Bouche, Qian Shi, Stephen N. Thibodeau, Josep Tabernero, Enrico Mini, Richard M. Goldberg, Gunnar Folprecht, Jean-Luc Van Laethem, Daniel J. Sargent, Steven R. Alberts, Pierre Laurent-Puig, Frank A. Sinicrope

Institutions: Hôpital Européen Georges-Pompidou, Université Paris Descartes, Fédération Francophone de Cancérologie Digestive, Centre Jean Perrin, Centre Hospitalier Universitaire de Reims, Mayo Clinic, Vall d'Hebron Hospital Universitari, University of Florence, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University Hospital Carl Gustav Carus, Erasmus Hospital, Inserm

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2296990247

Cites:

Cited by: 14

Related to: 10